ISSN:
1573-0646
Keywords:
piroxantrone
;
gastric adenocarcinoma
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Twenty-one evaluable patients with advanced gastric adenocarcinoma were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. One objective response was seen for an overall response rate of 5% (95% confidence interval 0–24%). Toxicities of grade ≥ 3 were primarily hematologie and seen in 13/21 patients. Piroxantrone has minimal activity against gastric adenocarcinoma and no further investigation of this agent on this schedule in this disease is recommended.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00874449